Show simple item record

dc.contributor.authorKim, Yu-Jin
dc.contributor.authorVenturini, Víctor
dc.contributor.authorDe la Torre, Juan C.
dc.date.accessioned2022-02-21T12:16:29Z
dc.date.available2022-02-21T12:16:29Z
dc.date.issued2021
dc.identifier.issn1999-4915spa
dc.identifier.urihttp://hdl.handle.net/10641/2843
dc.description.abstractMammarenaviruses are prevalent pathogens distributed worldwide, and several strains cause severe cases of human infections with high morbidity and significant mortality. Currently, there is no FDA-approved antiviral drugs and vaccines against mammarenavirus and the potential treatment option is limited to an off-label use of ribavirin that shows only partial protective effect and associates with side effects. For the past few decades, extensive research has reported potential anti-mammarenaviral drugs and their mechanisms of action in host as well as vaccine candidates. This review describes current knowledge about mammarenavirus virology, progress of antiviral drug development, and technical strategies of drug screening.spa
dc.language.isoengspa
dc.publisherVirusesspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectMammarenavirusspa
dc.subjectAntiviral drugspa
dc.subjectDrug repurposingspa
dc.subjectHigh-throughput screeningspa
dc.titleProgress in Anti-Mammarenavirus Drug Development.spa
dc.typearticlespa
dc.description.versionpost-printspa
dc.rights.accessRightsopenAccessspa
dc.description.extent1046 KBspa
dc.identifier.doi10.3390/v13071187spa
dc.relation.publisherversionhttps://www.mdpi.com/1999-4915/13/7/1187spa


Files in this item

FilesSizeFormatView
viruses-13-01187-v2.pdf1.021MbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España